R&D Brain-computer interfaces could redefine precision medicine BCIs could emerge as a ground-breaking tool for the pharma industry, offering new ways to understand and treat complex conditions.
News J&J abandons trial of atopic dermatitis drug J&J has discontinued a phase 2 trial of one of its pipeline candidates for atopic dermatitis, acquired in 2024 in a $1.25bn takeover deal.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.